|
1
|
Tripathi MK, Doxtater K, Keramatnia F,
Zacheaus C, Yallapu MM, Jaggi M and Chauhan SC: Role of lncRNAs in
ovarian cancer: Defining new biomarkers for therapeutic purposes.
Drug Discov Today. 23:1635–1643. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pearce CL, Stram DO, Ness RB, Stram DA,
Roman LD, Templeman C, Lee AW, Menon U, Fasching PA, McAlpine JN,
et al: Population distribution of lifetime risk of ovarian cancer
in the United States. Cancer Epidemiol Biomarkers Prev. 24:671–676.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Sharma S, Raghav R, O'Kennedy R and
Srivastava S: Advances in ovarian cancer diagnosis: A journey from
immunoassays to immunosensors. Enzyme Microb Technol. 89:15–30.
2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lisio MA, Lili Fu, Goyeneche A, Gao Z and
Telleria C: High-grade serous ovarian cancer: Basic sciences,
clinical and therapeutic standpoints. Int J Mol Sci.
20(952)2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Áyen A, Jiménez Martínez Y, Marchal JA and
Boulaiz H: Recent progress in gene therapy for ovarian cancer. Int
J Mol Sci. 19(1930)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kim S, Wang M, Tyrer JP, Jensen A, Wiensch
A, Liu G, Lee AW, Ness RB, Salvatore M, Tworoger SS, et al: A
comprehensive gene-environment interaction analysis in ovarian
cancer using genome-wide significant common variants. Int J Cancer.
144:2192–2205. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Temkin SM, Bergstrom J, Samim Gi and
Minasian L: Ovarian cancer prevention in high risk women. Clin
Obstet Gynecol. 60:738–757. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kurman RJ and Shih IM: The dualistic model
of ovarian carcinogenesis: Revisited, revised, and expanded. Am J
Pathol. 186:733–747. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kurman RJ: Origin and molecular
pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 24
(Suppl 10):x16–x21. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Rojas V, Hirshfield KM, Ganesan S and
Rodriguez-Rodriguez L: Molecular characterization of epithelial
ovarian cancer: Implications for diagnosis and treatment. Int J Mol
Sci. 17(2113)2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cancer Genome Atlas Research Network.
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim S, Han Y, Kim SI, Kim HS, Kim SJ and
Song YS: Tumor evolution and chemoresistance in ovarian cancer. NPJ
Precis Oncol. 2(20)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Toss A, Tomasello C, Razzaboni E, Contu G,
Grandi G, Cagnacci A, Schilder RJ and Cortesi L: Hereditary ovarian
cancer: Not only BRCA 1 and 2 genes. Biomed Res Int.
2015(341723)2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Testa U, Petrucci E, Pasquini L, Castelli
G and Pelosi E: Ovarian cancers: Genetic abnormalities, tumor
heterogeneity and progression, clonal evolution and cancer stem
cells. Medicines (Basel). 5(16)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ezzati M, Abdullah A, Shariftabrizi A, Hou
J, Kopf M, Stedman JK, Samuelson R and Shahabi S: Recent
advancements in prognostic factors of epithelial ovarian carcinoma.
Int Sch Res Notices. 2014(953509)2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shih IM and Kurman RJ: Ovarian
tumorigenesis: A proposed model based on morphological and
molecular genetic analysis. Am J Pathol. 164:1511–1518.
2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Moufarrij S, Dandapani M, Arthofer E,
Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A and Chiappinelli
KB: Epigenetic therapy for ovarian cancer: Promise and progress.
Clin Epigenetics. 11(7)2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kroeger PT Jr and Drapkin R: Pathogenesis
and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol.
29:26–34. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Okamura H and Katabuchi H:
Pathophysiological dynamics of human ovarian surface epithelial
cells in epithelial ovarian carcinogenesis. Int Rev Cytol.
242:1–54. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nakamura M, Obata T, Daikoku T and
Fujiwara H: The association and significance of p53 in gynecologic
cancers: The potential of targeted therapy. Int J Mol Sci.
20(5482)2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Erol A, Niemira M and Krętowski AJ: Novel
approaches in ovarian cancer research against heterogeneity, late
diagnosis, drug resistance, and transcoelomic metastases. Int J Mol
Sci. 20(2649)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mehra K, Mehrad M, Ning G, Drapkin R,
McKeon FD, Xian W and Crum CP: STICS, SCOUTs and p53 signatures; a
new language for pelvic serous carcinogenesis. Front Biosci (Elite
Ed). E3:625–634. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
25
|
Cortez AJ, Tudrej P, Kujawa KA and
Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother
Pharmacol. 81:17–38. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Patch AM, Christie EL, Etemadmoghadam D,
Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey
PJ, et al: Whole-genome characterization of chemoresistant ovarian
cancer. Nature. 521:489–494. 2015.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Slomovitz B, Gourley C, Carey MS, Malpica
A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun
CC, et al: Low-grade serous ovarian cancer: State of the science.
Gynecol Oncol. 156:715–725. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tarhriz V, Bandehpour M, Dastmalchi S,
Ouladsahebmadarek E, Zarredar H and Eyvazi S: Overview of CD24 as a
new molecular marker in ovarian cancer. J Cell Physiol.
234:2134–2142. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Charbonneau B, Goode EL, Kalli KR, Knutson
KL and DeRycke MS: The immune system in the pathogenesis of ovarian
cancer. Crit Rev Immunol. 33:137–164. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Piek JM, van Diest PJ, Zweemer RP, Jansen
JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G,
Kenemans P and Verheijen RH: Dysplastic changes in prophylactically
removed fallopian tubes of women predisposed to developing ovarian
cancer. J Pathol. 195:451–456. 2001.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Soong TR, Kolin DL, Teschan NJ and Crum
CP: Back to the future? The fallopian tube, precursor escape and a
dualistic model of high-grade serous carcinogenesis. Cancers
(Basel). 10(468)2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Weinberger V, Bednarikova M, Cibula D and
Zikan M: Serous tubal intraepithelial carcinoma (STIC)-clinical
impact and management. Expert Rev Anticancer Ther. 16:1311–1321.
2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Vang R, Shih IeM and Kurman RJ: Fallopian
tube precursors of ovarian low- and high-grade serous neoplasms.
Histopathology. 62:44–58. 2013.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Finch A, Shaw P, Rosen B, Murphy J, Narod
SA and Colgan TJ: Clinical and pathologic findings of prophylactic
salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol
Oncol. 100:58–64. 2006.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Gockley AA and Elias KM: Fallopian tube
tumorigenesis and clinical implications for ovarian cancer
risk-reduction. Cancer Treat Rev. 69:66–71. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Daly MB, Pilarski R, Berry M, Buys SS,
Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, et al:
NCCN guidelines insights: Genetic/familial high-risk assessment:
Breast and ovarian, version 2.2017. J Natl Compr Canc Netw.
15:9–20. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Dubeau L: The cell of origin of ovarian
epithelial tumours. Lancet Oncol. 9:1191–1197. 2008.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Powell CB, Kenley E, Chen L, Crawford B,
McLennan J, Zaloudek C, Komaromy M, Beattie M and Ziegler J:
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role
of serial sectioning in the detection of occult malignancy. J Clin
Oncol. 23:127–132. 2005.PubMed/NCBI View Article : Google Scholar
|
